Chemomab Therapeutics Adjourns Annual General Meeting to May 5, 2026 Due to Lack of Quorum
Chemomab Therapeutics Ltd. filed a Form 6-K on April 28, 2026, announcing the adjournment of its Annual General Meeting of Shareholders. Originally scheduled for April 28, 2026, at 4:30 p.m. Israel time, the meeting has been rescheduled to Tuesday, May 5, 2026, at the same time and location (Meitar | Law Offices, Ramat Gan, Israel). The adjournment was necessitated by a lack of a quorum required to conduct business. The meeting's agenda items and proposed resolutions remain as detailed in the proxy statement previously furnished to the SEC on March 20, 2026. This filing is incorporated by reference into the companyβs existing Registration Statements on Form F-3 and Form S-8. No changes to the proposed resolutions or clinical updates were provided in this specific filing. The announcement was signed by Sigal Fattal, the company's Chief Financial Officer.